myelodysplasia

(redirected from Myelodysplastic syndrome)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

myelodysplasia

[‚mī·ə·lō·dis′plā·zhə]
(medicine)
Abnormal spinal cord development, especially the lumbosacral portion.
References in periodicals archive ?
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).
Therapy related myelodysplastic syndrome has a myriad number of causes, but only limited numbers of typical cytogenetic presentation.
Epidemiology classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008; 87 : 691-9.
Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracycline.
Morphologic classification of the myelodysplastic syndrome (MDS): combined utilization of bone marrow aspirates and trephine biopsies.
Mutation of p53 gene does not play a critical role in myelodysplastic syndrome and its transformation to acute leukemia.
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.
[CD4.sup.+][CD25.sup.high] [Foxp3.sup.+] regulatory T cells in myelodysplastic syndrome (MDS)," Blood, vol.
[USPRwire, Fri Aug 21 2015] Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H1 2015', provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.
Filippo Petti, Chief Executive Officer, Celyad, said: Over the past few years Celyad has made great strides in evaluating our NKG2D-based CAR-T therapy for the treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. The FDA approval for the CYAD-02 IND application will allow us to evaluate new therapies in this difficult to treat population and the inclusion of an optimized shRNA developed using Horizons SMARTvector technology represents the output of a strong collaboration.
A 65-year-old female patient with myelodysplastic syndrome was hospitalized in our infectious diseases clinic for fever (38.5[degrees]C), chills and altered clinical state, which had all started 4 days previously.